Table 2.
Baseline Characteristics of Patients Treated with Lenvatinib
| Characteristic | All patients | PAI | No-PAI |
|---|---|---|---|
| No. | 13 | 7 | 6 |
| Age, years, mean ± SD | 65.46 ± 12.82 | 69.57 ± 5.65 | 60.67 ± 17.45a |
| >60 Years, n (%) | 10 (77) | 7 (100) | 3 (50) |
| ≤60 Years, n (%) | 3 (23) | 0 (0) | 3 (50) |
| Sex, n (%) | |||
| Female | 8 (61.5) | 5 (71.4) | 3 (50) |
| Male | 5 (38.5) | 2 (28.6) | 3 (50) |
| Weight, kg, mean ± SD | 70.59 ± 13.64 | 71 ± 13.2 | 70.12 ± 15.39a |
| Performance status, n (%) | |||
| ECOG 0 | 9 (69.2) | 5 (71.4) | 4 (66.7) |
| ECOG 1 | 4 (30.8) | 2 (28.6) | 2 (33.3) |
| Starting dose lenvima, mg, mean ± SD | 20.8 ± 4.93 | 22 ± 3.83 | 19.33 ± 6.02a |
| Follow-up, months, mean ± SD | 17.62 ± 10.22 | 20.71 ± 8.84 | 14 ± 11.3a |
| TSH, μIU/mL, mean ± SD | 0.095 ± 0.074 | 0.078 ± 0.083 | 0.115 ± 0.065a |
| ACTH, pg/mL, mean ± SD | 29.84 ± 9.4 | 31.9 ± 5.64 | 27.4 ± 12.7a |
| Cortisol, nmol/L, mean ± SD | 384.6 ± 73.86 | 396.5 ± 60.33 | 370.7 ± 91.08a |
| Peak cortisol, nmol/L (ACTH test), mean ± SD | 644.5 ± 81.53 | 600.9 ± 36.42 | 695.4 ± 90.01b |
| >646.6, n (%) | 1 (14.3) | 5 (83.3) | |
| ≤646.6, n (%) | 6 (85.7) | 1 (16.7) | |
a
No significant difference with PAI group.
b
Significant difference between PAI groups.
ACTH, adrenocorticotropic hormone; no-PAI, without primary adrenal insufficiency; SD, standard deviation; TSH, thyrotropin.